RxDoctor Payments Data

Talal Khan, MD

Internal Medicine · East Long Meadow, MANPI 1861406613

Payments from drug & device makers

$12,796in general payments, 2019–2025

Across 680 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • GSK$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$970
  • Novo Nordisk$851
  • Johnson & Johnson$639
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$12,775100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,796 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$262,950
Medicare patients
448
Services billed
3,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$100,914
JardianceEmpagliflozin69$77,100
JanuviaSitagliptin Phosphate71$72,848
OzempicSemaglutide75$72,224
TrulicityDulaglutide41$43,657
MounjaroTirzepatide35$42,041
FarxigaDapagliflozin Propanediol22$29,289
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$28,900
Breo ElliptaFluticasone/Vilanterol60$24,032
XareltoRivaroxaban19$15,143
RybelsusSemaglutide17$14,706
Atorvastatin Calcium672$12,083
TradjentaLinagliptin15$9,167
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$6,489
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$403$100,914127 claims
Novo NordiskOzempic, Rybelsus$851$86,93092 claims
Boehringer IngelheimJardiance, Tradjenta$266$86,26784 claims
Lilly USA, LLCTrulicity, Mounjaro$1,065$85,69876 claims
MerckJanuvia$77$72,84871 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,158$58,433115 claims
AstraZenecaFarxiga$970$29,28922 claims
Johnson & JohnsonXarelto$639$15,14319 claims
AbbVieSynthroid$3,842$3,02851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in East Long Meadow

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →